Pulsed electromagnetic field therapy in the management of knee OA

It seems most unusual that in a review of “all currently available treatments” for knee osteoarthritis (OA) by 21 authorities and “two experts in the field of guidelines methodology”, pulsed electromagnetic field therapy was not mentioned in the text or the 51 references.1 This is particularly troubling because over 2800 publications between 1966 and 1998 were retrieved. An identical search for efficacy of magnetic field therapy during this period listed 31 studies with at least one control group,2 including two double blind trials citing benefits in knee OA from a peer reviewed arthritis journal.3 In 1999 over 50 000 patients received pulsed signal therapy (PST) prescribed by over 1000 doctors at more than 300 clinics and hospitals in 16 countries, where it is usually reimbursed by fiscal intermediaries because of its proven record of cost effectiveness and safety. A summary of PST double blind and randomised study results in over 50 000 patients has been published,4 and findings in 100 000 patients (the vast majority with knee OA) have also been reported at recent international conferences.5 Although “alternative” remedies ranging from minerals, vitamins, nutritional supplements, and capsacin and diclofenac gels to sex hormones were discussed, in contrast with PST, none satisfied the category criteria the panel established to determine strong recommendation. Nor do any have the solid basic science studies that PST provides with its in vitro support for mechanisms of action to explain efficacy based on proteoglycan synthesis and chondrocyte stimulation results.6

Pulsed signal therapy is the result of three decades of research designed to characterise the piezoelectric signal that normally stimulates chondrocyte activity by creating a streaming potential in the extracellular matrix when bone is subjected to pressure. Although the transmission of this signal is impaired in OA, PST can reproduce this streaming potential in affected joints under no load, and in the nine one-hour daily non-invasive treatments are devoid of any adverse side effects. Long term follow up confirms sustained pain relief, improved mobility, and a high safety profile as assessed by validated instruments (WOMAC, OMERAC, modified Ritchie scales) as well as evaluations by doctors and patients.

My interest in PST began in 1995 when a Journal of Rheumatology article suggested that it might alleviate my 15 year old daughter’s pain caused by an arthritic condition. Although unable to walk without crutches, two weeks after a course of PST her pain was relieved and she could walk unassisted. A month later she was able to pursue all athletic activities without discomfort. She subsequently enrolled in a martial arts class, recently attained black belt status, and has continued to remain symptom free without the need for any drugs or further treatment for the past five years.

Although I am certified in cardiology and gastroenterology, a significant portion of my practice is now devoted to exploring how PST achieves its benefits.7 I have treated 1000 patients, most of whom had knee OA, with very gratifying results similar to those reported in the References. The panel cited two prior efforts to establish guidelines for treating knee OA, emphasising that these “primarily represent consensus statements from expert panels” and “The type and strength of evidence to support such guidelines remain unclear.” Their stated objective, therefore, was to “develop guidelines relating to clinical issues in OA management, and to indicate clearly the level of evidence to support individual statements”8. However, electromagnetic therapy approaches were again omitted, although at least one of the members is quite familiar with PST. The reason for this exclusion is not clear and I believe that your readership deserves to be aware of this extremely safe and effective option.

Treatment of women with aPL in pregnancy

I read with much interest the article of Derken et al in the January issue of the Annals of the Rheumatic Diseases.1 The authors gave a detailed introduction to the role of pulsed signal therapy in the treatment of pregnant patients with antiphospholipid syndrome (APS). Despite the presence of only a limited amount of data from controlled studies the authors gave helpful recommendations for the daily management of these patients.

However, there is a major concern with which I would like to deal. As we know the success of treatment of APS with oral anticoagulants very much depends on the strictness with which the dose is adjusted to the international normalised ratio. The authors rightly suggest changing from oral anticoagulants to subcutaneous low molecular weight heparin in pregnant patients with APS. However, I believe that the dose of low molecular weight heparin has to be adjusted in individual patients.

The measurement of anti-factor Xa activity in plasma enables us to calculate the dose of low molecular weight heparin which is needed to achieve optimal inhibition of the coagulation cascade. Values of 0.6-1.0 U/ml are believed to give maximum protection against thromboembolic events.

From my experience the optimal dose of low molecular weight heparin may be different in different patients. Moreover, a dose of 10 000 anti-Xa units given once daily rarely guarantees the desired value of anti-factor Xa activity and often a second injection has to be applied to achieve optimal effect. Therefore, as long as controlled data are missing I would suggest that the measurement of anti-factor Xa activity in pregnant patients with APS should be used to adjust the dose of low molecular weight heparin. This may result in better protection of mother and fetus in this disease.
Caudal epidural injections

Price et al recommend that caudal epidural injections should be carried out with x-ray screening. In practice the technique of performed in the outpatient clinic, where screening facilities are not usually available.


Authors’ reply

We thank Dr Fiehn for his interest and comments on our recent leader in the Annals. At present, there are insufficient data from randomised trials to give evidence based guidelines for optimal (prophylactic) treatment of many of the clinical manifestations of the antiphospholipid syndrome (APS). This not only holds for prevention of pregnancy related complications, the topic of our leader, but also for treatment of thrombosis related to antiphospholipid antibodies.

The major issue raised by Dr Fiehn is that he believes that in patients with APS one should use adjusted, not fixed, doses of low molecular weight heparin (LMWH). It is well known that anti-Xa activity relates to antithrombotic effects of LMWHs, and that the amount of LMWH needed to achieve and maintain a certain range of anti-Xa activity increases during the course of pregnancy. In most patients dose adjustment is needed in the second and, in some, in the third trimester (mean (SD) 20.5 (8.2) weeks), but individual patients vary widely in the time when the dose of LMWH needs to be adjusted from once to twice daily. Despite this, there is so far no clinical proof that for thromboprophylaxis in pregnancy or prevention of poor pregnancy outcome an adjusted dose LMWH (with cumbersome and costly monitoring of pre- and post-injection anti-Xa activity) is better than a fixed dose based on body weight. Therefore, we do not share Dr Fiehn’s view that one should advise adjusted doses of LMWH in all pregnant patients with APS.

R H W M DERKSEN
Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, The Netherlands

P G DE GROOT
Department of Haematology

H K NIEUWENHUIS
Department of Obstetrics and Gynaecology

G C M L CHRISTIAENS
Haemostasis and Thrombosis Laboratory


Interleukin 1 gene polymorphisms

I read with interest the recent article by Grilly and colleagues on the potential use of interleukin 1 (IL1) gene polymorphisms in predicting the need for joint surgery in patients with rheumatoid arthritis. Although the authors’ findings are certainly interesting and worthy of further investigation, I would like to raise a couple of points as to how these were arrived at in the first place.

When adopting the “candidate gene” approach in any disease association study, it pays to consider carefully the physiological context of a hypothesis. In this case the authors worked on the premise that one of the IL1 gene family polymorphisms investigated might correlate with disease outcome. These included polymorphisms both in the IL1 genes and the IL1 receptor antagonist (IL1ra) locus. The IL1ra is unique in being the only known endogenous cytokine receptor antagonist. The genes encoding IL1α, β...
and the IL1ra have co-evolved as a cytokine control mechanism: agents eliciting IL1 production generally induce IL1ra gene transcription as well, either directly or through a feedback loop triggered by IL1 itself. IL1ra competes with IL1 for binding to the cognate receptor, but produces no known signalling events upon binding. Additionally, one of the two IL1 receptors, type II, also lacks any known signalling capacity and is thought to function as a decoy binding site. It is assumed that polymorphisms found in various members of the IL1 gene family modify gene function then the implication is that they should be studied collectively, not individually. In support of this argument comes recent experimental evidence showing that plasma IL1ra levels are determined by allelic combinations within the IL1 gene family, as well as evidence for linkage disequilibrium between polymorphic markers spread across the IL1 gene family locus.

It is fair to say that Crilly and colleagues did allude in their paper to the possible existence of an extended IL1 gene family haplotype. However, there is already sufficient published evidence to justify examination of haplotype combinations of the investigated alleles in population studies.

On a different note, although the authors’ argument about the validity of surgery as a study end point is convincing, their selection of a 15 year disease duration free from surgery as the cut off point for this study seems dubious. A previous study by the same group had calculated that the median disease duration before surgery was 14.6 years, implying that there are a substantial number of patients in the “no surgery” group who will require surgery shortly after the 15 year time point, thereby potentially confounding any significant statistical findings. One might argue that the aim of this study was not to differentiate between patients that will or will not require surgery but, rather, to differentiate between rapid (<15 years) versus delayed (>15 years to surgery) disease progression. Even so, a more valid statistical approach might have been to analyse all patients as a single group and try to correlate genotype (or haplotype) with disease duration to surgery.


Secondly, for the statistical analysis we predefined early and late surgery. Analysis was undertaken after discussion with a qualified medical statistician. Should the correspondent wish to analyse our data, we would be happy to allow access if guarantees can be provided.

R MADHOK
Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 84 castle Street, Glasgow G4 0SF, UK

Author’s reply
I thank Dr Vamvakopoulos for his interest in our article1 and would like to make the following response.

We agree that testing for haplotype combinations of the interleukin 1 (IL1) gene family allele would be useful. However, for a large number of alleles to be tested a considerable sample size would be needed to correct for multiple allele testing. This would require a multicentre study; this is limited by funding constraints.

Secondly, for the statistical analysis we predefined early and late surgery. Analysis was undertaken after discussion with a qualified medical statistician. Should the correspondent wish to examine our data, we would be happy to allow access if guarantees can be provided.

LETTERS TO THE EDITOR

A case of shingles mimicking carpal tunnel syndrome

A 59 year old woman with an eight year history of seropositive erosive rheumatoid arthritis (RA) receiving sulfasalazine and penicillamine presented with severe sudden onset pain radiating from the left elbow to the left thumb, index and middle fingers. Examination disclosed synovitis of the left wrist, which might have caused median nerve compression. The wrist joint was injected with 20 mg of triamcinolone acetate with 1% lidocaine (lignocaine). She returned the following morning complaining of worsening pain. She was clinically well with no fever. White cell count was normal, but the erythrocyte sedimentation rate (ESR) was raised at 73 mm/1st h. A transcutaneous nerve-stimulating (TENS) machine was applied and she was prescribed amitriptyline 25 mg at night. The following day she had improved significantly but had developed a vesicular rash in the C6 dermatome consistent with herpes zoster infection (fig 1). Viral titres were consistent with current varicella zoster infection.

DISCUSSION
Establishing the cause of pain in patients with RA can be notoriously difficult. In addition to the psychological factors that influence pain perception, wrist and hand pain may result from rheumatoid synovitis, soft tissue inflammation, or mechanical nerve compression at wrist, elbow, and cervical spine. Herpes zoster infection is heralded by burning discomfort in a dermatomal distribution, which may occur for up to five days before the onset of the typical rash. Cervical dermatomes are affected in up to 15% of patients2 and may result in diaphragmatic paralysis and lower motor neurone paresis.3 In this case the occurrence of prodomal symptoms of herpes zoster mimicked the symptoms of carpal tunnel syndrome, presumed secondary to RA synovitis.

RA increases the risk of herpes zoster infection.4 In one series the use of low dose methotrexate, long duration of disease, and seropositivity were risk factors for subsequent infection.5 Gold treatment may also increase the likelihood of shingles.6

Immunocompromised patients should receive acyclovir early to avoid viral dissemination. In patients with RA the complexity of the differential diagnosis may delay diagnosis unless the possibility of herpes zoster infection is kept in mind.

Conflict of interest: none.

H WILSON
J HAMILTON
R MADHOK
Centre for Rheumatic Diseases, University Department of Medicine, Glasgow Royal Infirmary, Glasgow G31 2ER, UK

Correspondence to: Dr H Wilson
baryl@jngs.com

REFERENCES

2 Eisenberg SP, Brewer MT, Verderber E, Heimdahl P, Brandenbjer BJ, Thompson RC. Interleukin-1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism. Proc Natl Acad Sci USA 1994;91:5232–6.

3 Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated in polyarthritis as well, either directly or through a linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers. Am J Hum Genet 1998;62:1180–8.


fevers, gastrointestinal disturbances of nausea and vomiting, granulocytopenia, and hepatic cellular injury. More rarely, hypersensitivity can present with features of severe systemic infection and end organ dysfunction. Azathioprine is a commonly used immunosuppressive drug and is used in many medical specialties. Therefore recognising azathioprine hypersensitivity is important for all doctors. We report a case in which we suspect such an azathioprine hypersensitivity reaction.

A 32 year old Asian woman with mixed connective tissue disorder presented with a one day history of general malaise, fevers, and painful digits. Fourteen days earlier treatment had been started with azathioprine 50 mg daily, and her prednisolone increased from 5 mg to 15 mg daily owing to the development of proteinuria (1.5 g on 24 hour urine collection) and urticarial vasculitis on her lower legs.

On examination she was shocked, with a blood pressure of 70/30 mm Hg and had marked acrocyanosis (fig 1). The differential diagnosis included a lupus crisis or septic shock. She was treated in the intensive care unit with intravenous ceftriaxone, metronidazole, and prostacyclin for digital ischaemia after serial cultures were taken from all major sites. Staphylococcal toxic shock was excluded, with no growth on vaginal swabs and a negative staphylococcal toxin test. After negative cultures 1 g methylprednisolone was given for a possible flare up of her connective tissue disease. The azathioprine was discontinued. She improved despite concomitant intravascular coagulation. Multiple cultures from all sites did not identify any source of sepsis.

We suspected azathioprine hypersensitivity owing to:

- The timing of the patient’s illness in relation to the initiation of azathioprine
- The presence of recognised features of hypersensitivity—fever, chills, diarrhoea, hypotension, and hepatic dysfunction
- The effect of rechallenge. Three weeks after the presenting episode, one dose of azathioprine 25 mg was given for steroid-sparing effect (the initial illness was attributed to disease flare up); the patient had a more severe and rapid hypersensitivity response requiring treatment with intravenous corticosteroids.

She improved after treatment with high dose corticosteroids. No cultures ever isolated an infective source.

This case shows the importance of recognising azathioprine hypersensitivity. Approximately 50 cases have been reported in patients with immune mediated diseases such as inflammatory bowel disease, multiple sclerosis, and immune thrombocytopenias, where the initial illness is often ascribed to sepsis or reactivation of underlying disease. Most reactions occur in the first four weeks of drug initiation. Hypersensitivity should always be included in the differential of fever, hypotension, and renal failure. The case was reported to the Committee on Safety of Medicines (United Kingdom).

The mechanism of the reaction is unclear. Azathioprine is composed of a nitroimidazole attached to 6-mercaptopurine. It is proposed that the imidazole component causes hypersensitivity, while the 6-mercaptopurine may cause haematological side effects. However, there are conflicting reports about the component of the drug to which the hypersensitivity reaction can be attributed. Fields reviewed 49 cases, where the reaction occurred equally in men and women, aged 16–76 years, and there was a wide variation in azathioprine doses. All patients who developed shock were also taking corticosteroids.

Support for an allergic reaction is that it occurs in only a small percentage of patients, and the event recurs with drug rechallenge, as occurred inadvertently in our patient. Rechallenge with azathioprine is therefore dangerous and should be done under careful observation. A hapten from the imidazole component may bind to a protein molecule to elicit type 1 hypersensitivity. Reactions mimicking sepsis may result from increased production of mediators such as tumour necrosis factor.

N SOFAT
J HOUGHTON
J MCHALE
C S HIGGINS
Northwest London Hospitals NHS Trust,
Northwick Park Hospital, Watford Road,
Harrow HA1 3UJ, UK

Immunosuppressive treatment for vasculitis associated with Lyme borreliosis

Vasculitis of the central nervous system is a rare complication of Lyme borreliosis. We now report a case of early onset borrelia-associated encephalitis followed by systemic vasculitis. Antibiotics failed to improve the clinical course and remission was only reached after extensive immunosuppressive treatment.

A 52 year old man was admitted because of fever, headache, tinnitus, and painful joints. He reported a tick bite on his left arm, which had occurred three weeks earlier and which was followed by a reddish skin erosion. His general practitioner started treatment with doxycycline, but the patient’s condition worsened. The patient had a fever of 39.9°C, further physical examination showed no other abnormalities. Except for an erythrocyte sedimentation rate of 51 mm/1st h and a leucocyte count of 16.1x10^9/l, routine blood analysis was normal. Cultures (blood, urine, stool) were negative. Enzyme linked immunosorbent assays (ELISAs) showed an increased anti-borrelia-IgM titre of 322.5 EU/ml (normal <30) with normal IgG levels, suggestive of early stage Lyme borreliosis. This was supported by western immunoblotting, with reactivity towards anti-borrelia-IgM.

Ported by western immunoblotting, with reactivity towards anti-borrelia-IgM.

No spirochaetes were detected in this sample. Treatment with prednisolone (1 mg/kg/day) did not improve the condition of the patient within one week, therefore, cyclophosphamide (2 mg/kg/day) was added. Within two days the patient regained normal neurological functions. Renal function improved within four weeks (serum creatinine decreased from 56.4 to 24.4 mmol/l of urea) and the patient was weaned from the ventilator. Follow up was uneventful.

Vasculitis may develop within weeks after infection and complicate the clinical course of Lyme borreliosis. To our knowledge, this is the first description of a systemic vasculitis including cerebral and renal disease after B burgdorferi infection in a human being. Histological proof for vasculitis was assessed in a skin-fascia-muscle sample; the absence of spirochaetes therein suggests an autoimmune based pathogenesis. As in this case, laboratory support for acute B burgdorferi infection is an important issue, especially in areas like the Netherlands. Whether elicited directly by the micro-organism or by second ary autoimmune mechanisms, vasculitis occurs in association with disseminated organ failure. Cyclophosphamide, unsuccessful in the case of B burgdorferi induced cerebral vasculitis, was effective for this case of systemic vasculitis.

In conclusion, persisting vasculitic activity should be suspected whenever antibiotic treatment does not improve the clinical course in Lyme borreliosis. When borrelia associated vasculitis has been histologically established, and does not respond to corticosteroid treatment alone, we suggest the combined use of prednisolone and cyclophosphamide.

R KOMDEUR
J G ZIJLSTRA
T S VAN DER WERF
J M LIGTENBERG
J E TULLEKEN
Department of Internal Medicine, Intensive and Respiratory Care Unit (ICB), University Hospital Groningen, The Netherlands

Correspondence to: Dr J E Tulleken, Intensive and Respiratory Care Unit (ICB), Department of Internal Medicine, University Hospital Groningen, PO 30 001, 9700 RB Groningen, The Netherlands e.tulleken@int.azg.nl

Figure 1 Skin-fascia-muscle biopsy sample showing vasculitis of a medium sized artery and some necrosis of the vessel wall.

Bilateral transient osteoporosis of the knee in pregnancy

Transient osteoporosis of pregnancy involving the hips has been reported widely. The knee is much less commonly affected and only isolated cases have been reported. We report the case of a woman in the third trimester of pregnancy with bilateral transient osteoporosis of the knees.
A 36 year old woman presented with a one month history of pain in the left knee followed a week later by pain in the right. The right knee deteriorated over one to two weeks until she was unable to weight bear. There was no pain at rest. At the time of presentation she was 30 weeks pregnant with her first child conceived through in vitro fertilisation. There was no past history of joint problems, alcohol excess, corticosteroid use, preceding trauma, acute medical illness, or any constitutional symptoms. She walked with two crutches. Joint examination showed a slightly warm right knee with no clinical evidence of an effusion. Both knees were non-tender to palpation but painful at maximal flexion.

Investigations showed an erythrocyte sedimentation rate of 33 mm/1st h, C reactive protein slightly raised at 10 mg/l (normal <3), and globulins at 36 g/l (25–35) with a normal mentation rate of 33 mm/1st h, C reactive protein. Both knees were non-tender to palpation but painful at maximal flexion.

A diagnosis of transient osteoporosis of pregnancy was entertained and the patient was treated with simple analgesics and followed up closely throughout the remainder of her pregnancy. She presented to the delivery suite in labour at 39 weeks’ gestation and successfully delivered a healthy 4500 g male infant by fast normal vaginal delivery. By three weeks post partum the pain had begun to resolve and she could walk without any aids. At three months post partum there was only residual discomfort in the right knee walking up and down stairs. Repeat MRI of the knees showed dramatic improvement in the bone marrow oedema. In the right knee there was only minor patchy oedema in the distal femur and proximal tibia. In the left knee there was some residual spotty marrow inhomogeneity in the lateral tibial plateau.


Anticholesterol antibody levels in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE)—the prototype of immune complex diseases—is characterised by disturbances of the cellular and humoral immune systems. Antibodies against nuclear components are the hallmark of SLE, but a number of antibodies against proteins, glycoproteins, and carbohydrates have also been reported. Dyslipoproteinaemia and accelerated atherosclerosis, that commonly lead to coronary artery disease and other complications are recognised sequelae. The role of autoimmunity in the aetiology of atherosclerosis has recently been highlighted. Increased levels of antibodies against oxidised low density lipoprotein, lysophosphatidylcholine, and apolipoprotein A1 were found in patients with SLE. As reported earlier, we have shown marked alterations of anticholesterol antibody
(ACHA) levels in patients with various atherosclerotic vascular disorders. In this study ACHA levels of patients with SLE were compared with those of healthy donors.

Sixty eight patients (64 women, four men), aged 59.4 (10.6) (mean (SD)) years, who fulfilled at least four of the diagnostic criteria established by the American Rheumatism Association for SLE and 60 healthy donors (55 women, five men), aged 42.6 (8.1) years, were enrolled into the study. The SLEDAI (SLE Disease Activity Index) score was used to measure disease activity. Patients were considered to have active lupus if they scored at least 2 on the modified SLEDAI scale (calculated by omitting anti-dsDNA and complement C3 and C4) and prompt treatment was obviously indicated to control their symptoms.

The level of cholesterol-specific antibodies was measured by a solid phase enzyme immunoassay described earlier. Polystyrene plates (Greiner, Frickenhausen, Germany) were coated with 5 µg/well cholesterol dissolved in 100 µl absolute ethanol and incubated at 4°C for 24 hours. After washing with phosphate buffered saline (PBS) and blocking with 0.1% casein (Reanal, Budapest, Hungary) in PBS, the wells were incubated with 100 µl samples of serum diluted 1:800 in PBS containing 0.1% casein. The binding of ACHA to human atherosclerotic periadventitial conjugated γ-chain-specific rabbit antibodies (DAKO, Glostrup, Denmark) and with o-phenylendiamine (Sigma, St Louis, USA) using H2O2 as substrate. Optical density was measured at 492 nm (reference at 620 nm), and the mean of duplicates was calculated. Serial dilutions of purified immunoglobulin were used as standards in all experiments. Data obtained as optical density values were expressed in arbitrary units per millilitre (AU/ml), related to the standard curve. Our previous observations, in accordance with those of others, demonstrated the specificity of ACHA to cholesterol. The inter- and intra-assay variations of this method were 18.7% and 9.5%, respectively.

Differences between the parameters measured in controls and patients with SLE, between patients with active and inactive SLE, and those between patients with and without previous vascular events were calculated using the Mann-Whitney-test. The χ² test was used to estimate the discriminative power of ACHA between patients with SLE and healthy donors. The correlation of individual parameters with each other and with healthy donors. The correlation of power of ACHA between patients with SLE and those between patients with and without previous vascular events was calculated using Spearman's rank correlation test.

Twelve samples (18%) were classified as having been obtained from patients with active SLE and 56/68 (82%) from patients with inactive disease. Three of the 12 “active” samples were from patients with SLE active in more than one organ system and nine were from patients with disease activity in one organ system only (muscelskeletal, four), central nervous system (two), renal (two), and cutaneous (one). The difference between ACHA levels measured in the control group and in patients with SLE was significant (p<0.001) (fig 1).

High ACHA levels in the upper quartile occurred in 29/68 (43%) patients with SLE and 13/60 (22%) controls (p=0.012). ACHA levels (mean (SD)) of patients with active (97 (81) AU/ml) or inactive (64 (38) AU/ml) SLE did not differ significantly (p=0.21) and did not correlate with the SLEDAI score (r=0.22, p=0.066). No correlation was found between the ACHA level and other parameters (such as anti-dsDNA, CH50, C3, and C4, data not shown). No significant differences were found between patients treated with corticosteroids for inactive disease or those with inactive disease and not receiving corticosteroid treatment (p=0.17). The latter group had not received corticosteroids for at least one year before blood samples were obtained. The difference between the ACHA levels of patients who had or had not experienced vascular events was not significant.

The observed increases of ACHA levels may be related to underlying chronic inflammatory disease. A number of conditions such as dyslipoproteinemia, nephrotic syndrome, and changes in cholesterol membrane domains might have elicited the increase of ACHA levels. Corticosteroid treatment might also have stimulated ACHA production, though according to our observations this intervention does not alter ACHA levels significantly. A preventive role against atherosclerosis in patients with SLE has been attributed to raised ACHA levels, though these may also exert an atherogenic effect. Further studies are necessary to clarify the role of ACHA in the changes of lipid metabolism ascertained in patients with SLE.

This work was supported by grants OTKA No T 029044 (IK) and ETT No 259/2000 (LR).

Intravenous immunoglobulin for treatment of gastro-intestinal haemorrhage in dermatomyositis

Polyomyositis (PM) and dermatomyositis (DM) are systemic inflammatory disorders affecting skeletal muscles and other organs, especially the digestive tract. Oesophageal motor disturbances are common, occurring in as many as 25–60% of patients with PM/DM. Gastrointestinal disease is less recognised in PM/DM, though it may be responsible for life threatening complications—for example, dramatic haemorrhage, perforation, pseudo-obstruction, and pneumatoasis cystoides intestinalis, and spontaneous abdominal haematoma. We recently observed a new case, which is of particular interest. The patient who had DM refractory to steroids and both gastrointestinal haemorrhage related to vasculitis and oesophageal impairment due to DM experienced a rapid and complete resolution of all clinical manifestations of intravenous immunoglobulin treatment was started.

An 18 year old man had DM evolving from March 1999. The diagnosis of DM was made by the Bohan and Peter criteria: (a) symmetrical muscle weakness. Muscle power was gauged for eight proximal muscles (neck flexors, trapezius, deltoid, biceps, psoas, maximus and medius glutaeus, and quadriceps) by a modification of the British Medical Research Council Grading system, with a maximum theoretical score of 80 points. Muscle power of the patient was 72 points; (b) increased serum muscle enzymes—that is, creatine kinase (CK) 170 U/l (normal 5–130) and aldolase 7.2 U/l (normal 0.5–5); (c) myopathic changes on electromyography; (d) muscle damage on histological examination; and (e) characteristic dermatological manifestations—that is, heliotrope rash, perungual erythema, and poikiloderma.

Autoantibody screen was positive for anti-nuclear antibodies (ANA) with a value of 1/1000. Investigations, including pulmonary function tests, computed tomography scan of systemic lupus erythematosus. J Rheumatol 1999;26:2137–43.


the lungs, echocardiography, and abdominal ultrasound, were normal. Treatment with prednisone was started at a dose of 1 mg/kg daily. As both the clinical and biochemical status continued to deteriorate gradually, the steroid regimen was increased to a dose of 1.5 mg/kg daily from the 1st admission.

In July 1999 the patient presented with a two week history of dysphagia and melena evolving from one day. On admission, his two week history of dysphagia and melena were still present. Physical examination also showed cutaneous manifestations of DM and muscle weakness affecting both arms and legs. Muscle power of the patient was 65 points. Laboratory findings were as follows: erythrocyte sedimentation rate 50 mm/1st h, white blood cell count 10×10⁹/l, platelet count 490×10⁹/l, CK 3000 U/l, and aldolase 13.5 U/l. Findings of renal and liver tests, total protein, and albumin levels were normal. Autoantibody screening was negative for ANA >1:1000 with a speckled pattern; other tests, particularly for antibodies against rheumatoid factor, anti-cardiolipin and antiphospholipid antibodies, lupus-like anticoagulant, antineutrophil cytoplasmic antibodies, and cryoglobulin, were negative. Oesophageal manometry showed disorders of oesophageal peristalsis in the upper third of the oesophageal body and normal pressure in both upper and lower oesophageal sphincters. Gastroscopy demonstrated multiple small ulcerations affecting the stomach and the duodenum, with histology showing vasculitis of the small sized vessels.

A diagnosis of gastrointestinal haemorrhage related to vasculitis and oesophageal impairment due to DM was made. The patient was given intravenous immunoglobulin at a dose of 1 g/kg for two consecutive days monthly for six months. Prednisone was simultaneously decreased gradually to 5 mg every 15 days. The patient had no gastrointestinal haemorrhage recurrence, swallowing disorders and muscle strength improved rapidly, and the dermatological signs cleared.

In November 1999 methotrexate treatment was started at a dose of 30 mg weekly. At one year follow-up, the patient remains free of digestive, cutaneous, and muscle symptoms with methotrexate at a dose of 30 mg weekly and 12 mg prednisone daily.

Inflammatory oesophageal motor abnormalities predominate in patients with PM/DM and have been extensively described, involvement of the gastrointestinal tract is considered to be less common.1 In a review of 96 patients with DM, Downey et al found that only four patients had gastrointestinal manifestations.2 Our findings confirm that gastrointestinal impairment is a major cause of morbidity in PM/DM, as our patient presented with life threatening gastrointestinal haemorrhage. A diagnosis of gastrointestinal vasculitis related to DM could reasonably be made for our patient because the onset of DM and clinical deterioration and gastrointestinal vasculitis were consistent and the search for other causes of vasculitis (notably systemic vasculitides or other connective tissue disorders) proved negative.

Our report further highlights the importance of recognising gastrointestinal complications at an early stage in PM/DM, resulting in accurate diagnosis and management, and therefore decreasing both morbidity and mortality. The pathological mechanisms of gastrointestinal involvement are still not clearly understood in PM/DM, though it may be related to vasculitis of small sized vessels, leading to ischaemia, haemorrhage, and perforation of the gastrointestinal wall.3 4 Moreover, the present case is original, as our patient with DM and life threatening digestive impairment received intravenous immunoglobulin treatment, which prevented gastrointestinal haemorrhage recurring and produced dramatic and rapid remission of swallowing disorders. Other authors have also mentioned a favourable outcome with intravenous immunoglobulin treatment in patients with systemic vasculitis—for example, Churg-Strauss vasculitis, microscopic polyangiitis, and lupus erythematosus.5,6 In this instance, a limitation was the concomitant continuation of steroids during the entire period of intravenous immunoglobulin treatment. However, the improvement of all gastrointestinal symptoms may reasonably be related to intravenous immunoglobulin treatment in our patient with DM because the gastrointestinal manifestations deteriorated persistently despite high doses of prednisone as a single treatment. The beneficial effect of the accompanying methotrexate could also be excluded, as this later drug was started at the five month follow up of the patient.

Finally, our findings indicate that intravenous immunoglobulin should be considered the best treatment in both gastrointestinal haemorrhage related to vasculitis and oesophageal dysfunction due to steroid refractory DM, such a treatment offering the advantages of efficacy and good tolerance. However, no definite conclusion can be drawn and further controlled trials with a large number of patients with PM/DM are required to establish optimal doses and effective management.

1 I MARIE H LEVESQUE N CAILEUX H COURTOIS H LEVESQUE C GUÉDON
Department of Internal Medicine, Centre Hospitalier Universitaire de Rouen-Boisguillaume, 76031 Rouen Cedex, France
Correspondence to: Dr I Marie, 16 rue Arthur Duval, 76300 Sotteville-lès-Rouen, France

Sjögren’s syndrome: an unusual cause of Bell’s palsy

The most common form of facial paralysis is idiopathic—that is, Bell’s palsy. Sjögren’s syndrome (SS), a chronic inflammatory disorder characterised by lymphocytic infiltration of exocrine glands resulting in the so-called “sicca complex”, is a rare secondary cause of this self limiting illness. Primary SS includes mostly peripheral, and to a lesser extent central, autonomic neuropathy and central nervous system involvement.1 A patient with unilateral facial palsy, autoimmune hypothyroidism, and Sjögren’s syndrome is presented.

A 41 year old woman developed right sided facial numbness, described as “dentist anaesthesia for tooth extraction”. One day later she had a reduced sense of taste and right facial weakness. General physical examination was not remarkable. Neurological examination showed anisocoria, peripheral right sided facial paresis, reduced sense of taste on the right half of the tongue, and dysaesthesia in the region of the second segment of the right trigeminal nerve.

Although the erythrocyte sedimentation rate (ESR) was 30 mm/1st h, routine laboratory investigations were normal. Herpes simplex infection, including IgG, IgG index, and oligoclonal or extra bands on electrophoresis, was not abnormal. Screening tests for herpes simplex and varicella virus, syphilis, and borrelia in the serum and in the liquor were negative. Magnetic resonance imaging (MRI) of the brain showed no abnormalities. Nerve conduction studies showed peripheral facial paresis. She recovered spontaneously from her symptoms within six weeks, however, during follow up the raised ESR persisted.

Review of her medical history uncovered complaints of burning eyes and dry mouth, slight weight gain, and cold intolerance. There was a family history of androgenetic alopecia. She denied using any drugs previously. A strongly positive anti-extracellular antigen (ENA)/SS-A antibodies test was shown on further investigation, with negative tests for antinuclear factor/anti-SS-A antibodies/rheumatoid factor and RNP/SS-B/Sm antibodies. Rose-Bengal staining showed corneal punctate lesions (van Bijsterveld score 6). Lower labial biopsy showed histopathological findings matching the diagnosis of SS with a
focus score of one lymphocyte focus for 4 mm² salivary gland tissue. Additionally, thyroid function tests showed a raised thyroid stimulating hormone (11 mU/L), low free thyroxine (13.0 pmol/l) with positive antithyroid microsomal antibodies and negative antithyroglobulin antibodies.

The clinical, serological, and histopathological manifestations fulfilled the European study group criteria for the diagnosis of SS. The patient was treated with artificial tears and thyroxine supplements that returned her thyroid function tests to normal.

Prevalence of neuropathy in patients with SS ranges from 10 to 50%. Polyneuropathy can be the first clinical manifestation of SS and may even precede sicca symptoms in 40% of patients. However, less frequently, cranial neuropathy can occur with a predisposition to involvement of the trigeminal nerve. The vasculitic damage to vaso nervorum documented by pathological studies is associated with a higher incidence of serum anti-SS-A (Ro) antibodies. The association of SS with autoimmune thyroid disease (AITD) is well recognized. AITD and SS share similarities in the immunopathology in addition to their genetic linkage to the HLA-DR3/DR4 alleles. Only nine cases of facial nerve involvement associated with SS have been described previously.

This case illustrates how facial palsy disclosed the primary SS as an underlying systemic disorder. To our knowledge the combination Bell’s palsy as presenting feature in a patient with SS, and hypothyroidism secondary to AITD has not been reported hitherto.

M HADITHI  
F STAM  
AJ M DONKER  
Department of Internal Medicine

B A C DJIKMANES  
Department of Rheumatology, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands

Correspondence to: M Hadithi, Department of Internal Medicine, Academic Hospital Vrije Universiteit, P O Box 7057, 1007 MB Amsterdam, The Netherlands.

m.hadithi@azvu.nl


Table 1  
a, Antitrypsin phenotypes in ANCA* (anti-PR3* or anti-MPO*) positive patients

<table>
<thead>
<tr>
<th>Phenoypes</th>
<th>All ANCA+ (N=157)</th>
<th>Anti-PR3+ (N=60)</th>
<th>Anti-MPO+ (N=97)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Homozygous M</td>
<td>99(63)</td>
<td>36(60)</td>
<td>36(63)</td>
</tr>
<tr>
<td>- M1 M1</td>
<td></td>
<td>36(60)</td>
<td>36(63)</td>
</tr>
<tr>
<td>- M2 M2</td>
<td></td>
<td>4(3)</td>
<td>2(2)</td>
</tr>
<tr>
<td>- M3 M3</td>
<td></td>
<td>0(0)</td>
<td>0(0)</td>
</tr>
<tr>
<td>- M4 M4</td>
<td></td>
<td>0(0)</td>
<td>0(0)</td>
</tr>
<tr>
<td>Heterozygous M</td>
<td>58(37)</td>
<td>22(36)</td>
<td>36(37)</td>
</tr>
<tr>
<td>- M1 M2</td>
<td></td>
<td>20(33)</td>
<td>28(29)</td>
</tr>
<tr>
<td>- M1 M3</td>
<td></td>
<td>0(0)</td>
<td>0(0)</td>
</tr>
<tr>
<td>- M1 M4</td>
<td></td>
<td>0(0)</td>
<td>0(0)</td>
</tr>
<tr>
<td>- M2 M3</td>
<td></td>
<td>2(1)</td>
<td>2(1)</td>
</tr>
<tr>
<td>Other heterozygous</td>
<td></td>
<td>12(20)</td>
<td>11(12)</td>
</tr>
<tr>
<td>- M1 S</td>
<td></td>
<td>2(1)</td>
<td>2(1)</td>
</tr>
<tr>
<td>- M2 S</td>
<td></td>
<td>0(0)</td>
<td>0(0)</td>
</tr>
<tr>
<td>- M4 other</td>
<td></td>
<td>0(0)</td>
<td>0(0)</td>
</tr>
<tr>
<td>Total</td>
<td>157(100)</td>
<td>60(100)</td>
<td>97(100)</td>
</tr>
</tbody>
</table>

*ANCA = antineutrophil cytoplasmic antibody; PR3 = proteinase 3; MPO = myeloperoxidase.
associated diseases in southern Chinese
among whom anti-MPO predominated.
S S LEE
J W M LAWTON
K H KO
Department of Pathology,
The University of Hong Kong,
Queen Mary Hospital Compound,
Pohfalam Road,
Hong Kong Special Administrative Region,
China
Correspondence to: Dr S S Lee, 5/F Yaumatei
Jockey Club Clinic, 145 Battery Street, Yaumatei,
Kowloon, Hong Kong SAR
microszi@health.gov.hk

1 Ensailet VL, Testa A, Audrain M, Roge C,
Hamidou M, Barrier JH, et al. Alpha 1-anti-trypsin
genetic polymorphism in ANCA-positive systemic vasculitis.
2 Griffith ME, Laurence JU, Gaskin G, White-
house DB, Pusey CD. C-antineutrophil cyto-
plasmic antibody positivity in vasculitis pa-
tients associated with the Z allele of an anti-
titransferrin, and P-antineutrophil cytoplasmic
antibody positivity with the S allele. Nephrol
3 Savage JA, Chang L, Cook L, Burden J, Daska-
lakis M, Dozy J. Alpha 1-anti-trypsin defi-
ciency and anti-protease 3 antibodies in anti-
neutrophil cytoplasmic antibody (ANCA)-
associated systemic vasculitis. Clin Exp
4 Elsdon A, Matheson J, Alliston S, Letheby N,
Wieslander J, Lindgren S. The prevalent clini-
cal significance of anti-1-anti-trypsin deficiency
(P2) and ANCA specificities (protease 3,
BPI) in patients with ulcerative colitis. Inflamm
5 Ying QL, Liang ZQ. Allelic frequencies of
PR3 associated disease in southern Chinese
Matters arising, Letters
í
5 Ying QL, Liang ZQ. Allelic frequencies of
PR3 associated disease in southern Chinese
í
5 Ying QL, Liang ZQ. Allelic frequencies of
PR3 associated disease in southern Chinese
í
5 Ying QL, Liang ZQ. Allelic frequencies of
PR3 associated disease in southern Chinese
í
5 Ying QL, Liang ZQ. Allelic frequencies of
PR3 associated disease in southern Chinese
í
5 Ying QL, Liang ZQ. Allelic frequencies of
PR3 associated disease in southern Chinese
í
PR3 associated disease in Hong Kong. Post-
6 World Health Organization. 01-Anti-trypsin
deficiency: memorandum from a WHO meet-
ing. Bull World Health Organ 1997;75:
397–415.
7 Lee SS, Lawton JWM. Heterogeneity of anti-
PR3 associated disease in Hong Kong. Post-

A case of cholesterol
embolism with ANCA
treated with corticosteroid
and cyclophosphamide

We report a case of a patient with cholesterol
embolism who showed positive for both
myeloperoxidase and anti-neutrophil cytoplasmic
antibody (MPO-ANCA) and proteinase 3
antineutrophil cytoplasmic antibody (PR3-
ANCA) and who was treated with predni-
solone (PSL) and cyclophosphamide.

A 50 year old man underwent cardiac catheterisation for back pain. The examination
disclosed 90% stenosis of the right coro-
nary artery and a saccular aneurysm in the thoracic aorta. The patient underwent percu-
taneous transluminal coronary angioplasty and the aneurysm was wrapped with an arti-
ficial blood vessel. Postoperatively, the patient had a fever, pleural effusion, abdominal pain,
and increased white blood cell (WBC) count, C reactive protein (CRP), and serum creati-
geate (nine (710 µmol/l), and CRP (11.3 mg/l).
complements components were within nor-
mal ranges. PR3-ANCA and MPO-ANCA were high at 82E and 29E, respectively.
Complementary treatment of cholesterol embolism: a pseudovasculitic syndrome. Semin
4 Thadani R, Camargo C Jr, Xavier R, Fang L,
Bazari H. Atheroembolic renal failure after
invasive procedures. Natural history based on
56 patients with acute deterioration of renal function. Cy-
lophosphamide and PSL improved the symp-
toms, but cyclophosphamide was discontinu-
ated and the PSL dose was reduced because
renal and skin biopsies showed cholesterol
embolism. Subsequently, the patient died of
intractable cardiac failure.
Kaplan-Pavlovcic et al reported two cases of
renal failure with positive MPO-ANCA. The
details are unknown for one patient. The
other patient was treated with corticosteroid
alone. This patient required haemodialysis
and amputation of the toes. Although their
treatment did not result in the improvement
of vasculitis, the combination of PSL and
cyclophosphamide was effective in our pa-
ient with ANCA.
This result suggests that active treatment
with corticosteroid and cyclophosphamide
should be considered in ANCA positive cases
of cholesterol embolism.

E MAISHIMA
Y YAMADA
M MUNE
Y YUKAWA
Third Department of Internal Medicine,
Wakayama Medical College,
811-1, Kimiidera, Wakayama City,
Wakayama 641-0012, Japan
Correspondence to: Dr Maeshima

1 Fine MJ, Kapoor W, Falanga V. Cholesterol
crystal embolization: a review of 221 cases in
the English literature. Angiology 1987;38:768–
84.
2 Lie JT. Vasculitis look-alikes and pseudovasculi-
this syndromes. Curr Diagnos Pathol 1995;2:
78–5.
3 Cappiello RA, Espinoza LR, Adelman H, Agui-
azar J, Vasey PB, German BF. Cholesterol
embolism: a pseudovasculitic syndrome. Semin
4 Thadani R, Camargo C Jr, Xavier R, Fang L,
Bazari H. Atheroembolic renal failure after
invasive procedures. Natural history based on
56 historically proved cases. Medicine (Bal-
5 Peat DS, Matheson JW. Cholesterol emboli
may mimic systemic vasculitis. BMJ 1996;313:
546–7.
6 Kaplan-Pavlovic S, Viziak A, Vene N, Ferluga
D. Antineutrophil cytoplasmic autoantibodies
in atheroembolic disease. Nephrol Dial Trans-
HLA-DRB1*0301 and DQA1*0501 in RA

Auranofin is an oral gold preparation used in the treatment of rheumatoid arthritis (RA). During treatment, proteinuria has been reported in approximately 3% of patients. In a few cases in which renal biopsies were performed, a membranous nephropathy was shown to have developed. Several anti-rheumatic agents have been reported to induce renal manifestations or drug induced lupus reactions, or both, in patients with RA. In these subjects a genetic predisposition for HLA has previously been suggested.

To determine whether similar genetic factors might be operative in auranofin induced nephropathy, we analysed the HLA-DRB1, DQA1, and DQB1 alleles using a polymerase chain reaction. Furthermore, we investigated if the renal side effects were associated with serological findings in accordance with systemic lupus erythematosus (SLE), thus indicating the development of a drug induced lupus reaction.

Six patients (three female, three male) who developed biopsy proven membranous nephropathy or significant proteinuria (>0.5 g/day) during treatment with auranofin are reported. All patients met the American College of Rheumatology criteria for RA. The median age before onset of auranofin treatment was 72 (52–83) years, 4/6 patients were rheumatoid factor positive and 2/5 patients were antinuclear antibody (ANA) positive. The median duration of auranofin treatment before the onset of proteinuria was 5 (4–10) months.

During auranofin treatment, two patients developed an increased ANA titre (1/200 and 1/1600) but no antibodies against anti-dsDNA, SSA/SSB, Sm, or RNP were detected. None of the patients developed an increased serum creatinine level. After withdrawal of auranofin, proteinuria decreased significantly or disappeared in all cases.

Table 1 presents the HLA alleles.

A high frequency of the alleles associated with SLE—namely, DRB1*0301 (DR3), DQA1*0501, and DQB1*0201, was recorded in the patients developing membranous nephropathy or proteinuria during auranofin treatment. Of these, DRB1*0301 and DQA1*0501 occurred in 4/6 of the patients, and 5/6 patients carried at least one of these alleles.

The importance of DR3 or DQA1*0501 in drug induced renal manifestations has previously been suggested in patients with penicillamine and sodium aurothiomalate induced renal side effects. Also, in accordance with these findings, the DQA1*0501 and DRB1*0301 alleles have been recorded in a high frequency in patients developing sulfasalazine induced nephritis.

In two cases the development of membranous nephropathy was accompanied by a simultaneous increase in the ANA titre, thus indicating development of a drug induced SLE reaction. However, both patients had previously presented some sign of an autoimmune reactivity pattern, which may confer a risk factor in the treatment with certain anti-rheumatic drugs in RA.

Simultaneous treatment with sulfasalazine had been given in two cases, but as the sulfasalazine treatment period was either limited, or lacked any time relation with the onset of proteinuria, it seems unlikely that the patients developed a drug reaction against sulfasalazine. Further arguments rejecting the possibility of a sulfasalazine induced drug reaction are the lack of anti-dsDNA antibodies and the rapid onset of proteinuria among the patients, thus contrasting with the findings reported in sulfasalazine induced SLE.

The mechanism for induction of membranous nephropathy during auranofin treatment is unknown. Interestingly, it has been suggested that gold can bind to and alter major histocompatibility complex-peptide complexes, thus giving a possible explanation of both beneficial effects as well as side effects during treatment. Another possibility is that auranofin may alter the cytokine pattern towards an SLE-like phenotype and thus facilitate the development of SLE associated manifestations in genetically susceptible subjects. In accordance with this hypothesis, auranofin or other gold preparations have been reported to inhibit the production of interleukin 1 (IL1), tumour necrosis factor α, and IL2. The effects on IL10, a cytokine reported to be increased in both patients with idiopathic SLE and their healthy relatives as well as in patients developing sulfasalazine induced SLE-like reactions, is unknown, however.

In conclusion, the data suggest that SLE related HLA alleles, with special focus on DRB1*0301 and DQA1*0501, may predispose to development of renal side effects or drug induced lupus reactions during treatment with auranofin, as also previously recorded during treatment with other anti-rheumatic agents. Development of drug induced SLE, here reported for the first time, may occur during auranofin treatment.